Market closed

Compass Therapeutics/$CMPX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Compass Therapeutics

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Ticker

$CMPX
Trading on

Industry

Biotechnology

Employees

35

CMPX Metrics

BasicAdvanced
$222M
-
-$0.36
1.00
-
$222M
1
$4.08
$0.77
1.8M
14.96
14.28
5.027
5.297
-23.81%
-36.07%
259.415
1.77
1.77
-4.911
7.43%
-34.97%

What the Analysts think about CMPX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.

CMPX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CMPX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CMPX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Compass Therapeutics stock?

Compass Therapeutics (CMPX) has a market cap of $222M as of April 05, 2025.

What is the P/E ratio for Compass Therapeutics stock?

The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of April 05, 2025.

Does Compass Therapeutics stock pay dividends?

No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of April 05, 2025.

When is the next Compass Therapeutics dividend payment date?

Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Therapeutics?

Compass Therapeutics (CMPX) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.